Transcript • Feb. 10, 2026 11:45 AM • AstraZeneca PLC (AZN)
Transcript
Feb. 10, 2026 11:45 AM
AstraZeneca PLC (AZN)
Pascal Soriot: 2025 was a year of continued strong commercial performance and exceptional pipeline delivery for AstraZeneca. Total revenue increased by 8%, with product revenue up 10%, reflecting broad-based growth across all therapy areas and major regions. This performance supported an 11% increase in core earnings per share. The momentum we have built is set to continue, with more than 20 phase 3 trial readouts anticipated in 2026 alone, as we advance our pipeline to bring new medicines and indications to patients around the world. Our sustained progress means we remain firmly on track to deliver our 2030 ambition, and we are making excellent progress with transformative technologies that have the potential to drive our growth beyond 2030. Thank you to the entire AstraZeneca team for your dedication and your commitment as we continue to make a difference for people, society and the planet.
